Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H15NO2.ClH |
Molecular Weight | 205.682 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(=O)OC1CN2CCC1CC2
InChI
InChIKey=LWWSARSTZGNKGV-UHFFFAOYSA-N
InChI=1S/C9H15NO2.ClH/c1-7(11)12-9-6-10-4-2-8(9)3-5-10;/h8-9H,2-6H2,1H3;1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10411607Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411607
Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411607
Curator's Comment: Known to be CNS penetrant in mouse; rats. Human data not available
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4917903
Curator's Comment: Aceclidine was first prepared in 1960
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
17.0 µM [EC50] | ||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
|||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Glaunorm Approved UseGlaucoma, in its different clinical forms Launch Date1969 |
Sample Use Guides
Instill 2 drops of Glaunorm (2% aceclidine hydrochloride solution) into the conjunctival sac every 8 hours following the doctor's prescription
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10845594
Human eyes were dissected and perfused. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 1 nM to 10 mM of aceclidine, were added to the perfusion medium. Outflow facility increased from baseline facility in eyes treated with aceclidine at lower concentrations (1 nM to 1 uM) but remained unchanged at higher concentrations.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000078824
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
m9469
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
C96880
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
228-071-5
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
SUB00241MIG
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
DTXSID30976587
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
6109-70-2
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
3B22O325Q6
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
170367
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD